The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1360
March 21, 2011
View Complete Issue         Table of Contents 2019 
Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
March 21, 2011 (Issue: 1360)
Metformin (Glucophage, and others) is generally preferred as the first-line agent for treatment of type 2 diabetes, but most patients subsequently require treatment with more than one drug. Many combination products have been marketed; the latest of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Saxagliptin/Metformin (Kombiglyze XR) for Type 2 Diabetes
Article code: 1360a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.